Condition: Atherosclerosis · Inflammation · Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
The goal of this randomized, double blind, placebo controlled trial is to study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.
This description comes directly from the study's public registry record.
Cheyenne Y.Y. Beverloo, MD · +31205669111 · c.y.beverloo@amsterdamumc.nl
Always discuss trial participation with your own doctor first.
| Amsterdam UMC, location AMC | Amsterdam, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06263244